| Not Yet Recruiting | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Neuroblastoma | Phase 2 | 2026-07-31 |
| Recruiting | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Neuroblastoma | Phase 2 | 2024-12-16 |
| Active Not Recruiting | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells Neuroblastoma | Phase 1 | 2019-01-14 |
| Completed | MIBG With Dinutuximab +/- Vorinostat Neuroblastoma | Phase 1 | 2018-09-12 |
| Completed | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Neuroblastoma | Phase 1 | 2017-09-05 |
| Active Not Recruiting | Neuroblastoma Precision Trial Neuroblastoma | — | 2016-08-22 |
| Active Not Recruiting | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma Neuroblastoma | Phase 1 | 2015-10-08 |
| Terminated | SF1126 for Patients With Relapsed or Refractory Neuroblastoma Neuroblastoma | Phase 1 | 2015-07-09 |
| Completed | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Neuroblastoma | Phase 2 | 2014-07-01 |
| Completed | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Neuroblastoma | Phase 1 | 2014-01-16 |
| Completed | Study of MLN8237 in Combination With Irinotecan and Temozolomide Neuroblastoma | Phase 1 / Phase 2 | 2012-05-01 |
| Recruiting | Neuroblastoma Biology Study Neuroblastoma | — | 2011-07-01 |
| Completed | N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Neuroblastoma | Phase 1 | 2010-03-01 |
| Completed | N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuro Neuroblastoma | Phase 1 | 2009-12-01 |
| Completed | N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma Neuroblastoma | Phase 1 | 2007-01-01 |
| Completed | N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Neuroblastoma | Phase 1 | 2006-12-01 |
| Completed | N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Neuroblastoma | Phase 1 | 2005-12-01 |
| Completed | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neurob Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma | Phase 1 | 2004-05-01 |
| Completed | N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplanta Neuroblastoma | Phase 1 | 2004-03-01 |
| Completed | N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma Neuroblastoma | Phase 1 | 2003-08-01 |
| Completed | N99-02: Melphalan and Buthionine Sulfoximine Neuroblastoma | Phase 1 | 2001-08-01 |
| Completed | N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With N Neuroblastoma | Phase 1 | 2000-05-01 |
| Completed | Chemotherapy in Treating Children With Neuroblastoma Neuroblastoma | Phase 1 | 1996-06-01 |